Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer

BACKGROUND: Docetaxel improves symptoms and survival in metastatic castration-resistant prostate cancer (CRPC). However, ∼50% of patients are chemoresistant. This study examined whether changes in cytokine levels predict for docetaxel resistance in vitro and in a clinical cohort. METHODS: PC3 cells...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Mahon, K L, Lin, H-M, Castillo, L, Lee, B Y, Lee-Ng, M, Chatfield, M D, Chiam, K, Breit, S N, Brown, D A, Molloy, M P, Marx, G M, Pavlakis, N, Boyer, M J, Stockler, M R, Daly, R J, Henshall, S M, Horvath, L G
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2015
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4402456/
https://ncbi.nlm.nih.gov/pubmed/25867259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.74
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados